Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilars

Set Alert for Biosimilars

Slovenia Is Our Commitment; Evotec Is A Gamechanger: Sandoz’s Stenico

On the sidelines of Medicines for Europe’s 19th biosimilar conference in Amsterdam, Sandoz global biosimilars chief Peter Stenico spoke to Generics Bulletin about the firm’s preparations and strategy ahead of its proposed spinoff from Novartis later this year.

Biosimilars Strategy

MGC And GlycoNex Kick Off Denosumab Trial In Japan

Mitsubishi Gas Chemical Company and GlycoNex have begun a Phase I trial in Japan for their SPD8 denosumab biosimilar. The partners are also “actively pursuing global development plans” for the rival to Prolia and Xgeva.

Biosimilars Clinical Trials

Dr Reddy’s Takes Another Step Forward On Tocilizumab

Dr Reddy’s has notched up another achievement for its biosimilar tocilizumab candidate, after the intravenous presentation of the firm’s proposed Actemra/RoActemra rival completed a Phase I study.

Biosimilars Clinical Trials

Generics Bulletin Explains: Sandoz’s Spinoff From Novartis

Ahead of a Sandoz capital markets day on 8 June, Generics Bulletin explains what we know so far about the firm’s spinoff from parent company Novartis – as well as the questions that the companies are yet to answer.

Strategy Deals

Stada Gets FDA Nod For US Epoetin Alfa Supply

Stada has received US FDA approval to supply the Retacrit epoetin alfa biosimilar to partner Pfizer for the US market, allowing it to expand on an existing European supply arrangement.

Biosimilars Deals

Lupin Launches First Cetuximab Biosimilar In India Through Enzene Partnership

Lupin has collaborated with Alkem subsidiary Enzene Biosciences to launch the first ever cetuximab biosimilar in India. 

Biosimilars Launches

Coherus Plots ‘Lowest Price Adalimumab’ With Huge Discount, Ties Up With Mark Cuban

Coherus BioSciences had teased a “compelling value proposition” for its Yusimry (adalimumab-aqvh) biosimilar to AbbVie’s Humira blockbuster and it has delivered, with a pair of pricing strategies include one though an alliance with self-labelled “disruptor” Mark Cuban.

Biosimilars Pricing Strategies

What’s Next? Five Things To Look Out For In June

Generics Bulletin previews the most notable and anticipated events for June 2023.

Biosimilars Generic Drugs

Biocon Pumps Up For Adalimumab US Debut Amid Payer ‘Steady State’

Biocon is confident of its “four channel strategy” for the upcoming debut of biosimilar Humira in the US and also asserts it’s well positioned to compete when price cuts come into play for Sanofi’s Lantus next year.

Sales & Earnings Commercial
See All
UsernamePublicRestriction

Register